Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Camp Lejeune Cases
  • Drug Injury
  • Free Case Evaluation
  • About Us

New Analysis Finds An Increased Risk Of Bladder Cancer For Jardiance

November 13, 2017 By Law Offices of Thomas J. Lamb, P.A.

This article, “SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials”, was published in the October 2017 edition of Diabetologia. It presents the findings of medical researchers who conducted a systematic literature review to identify randomized controlled trials that reported cancer events in Type-2 diabetes patients treated with Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitors for at least 24 weeks.

From the Abstract for this Diabetologia medical journal article:

Results: In total, 580 incidences of cancer among 34,569 individuals were identified from 46 independent RCTs with a mean trial duration of 61 weeks. When compared with comparators (placebo or other active glucose-lowering treatments), SGLT2 inhibitors were not significantly associated with an increased risk of overall cancer (OR 1.14 [95% CI 0.96, 1.36]). For pre-specified cancer types, the risk of bladder cancer might be increased with SGLT2 inhibitors (OR 3.87 [95% CI 1.48, 10.08]), especially [Jardiance (empagliflozin)] (OR 4.49 [95% CI 1.21, 16.73]). Interestingly, [Invokana (canagliflozin)] might be protective against gastrointestinal cancers (OR 0.15 [95% CI 0.04, 0.60). [Emphasis added.]

For years there has been a lingering concern over whether SGLT2 inhibitors are associated with the development of bladder cancer.

This recent medical journal article singles out the SGLT2 inhibitors which contain the active ingredient empagliflozin, which are listed below:

  • Jardiance (empagliflozin) — Boehringer Ingelheim Pharmaceuticals — FDA Approval: 2014
  • Glyxambi (empagliflozin and linagliptin) — Boehringer Ingelheim Pharmaceuticals — FDA Approval: 2015
  • Synjardy (empagliflozin and metformin hydrochloride) — Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company — FDA Approval: 2015
  • Synjardy XR (empagliflozin and metformin hydrochloride) — Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company — FDA Approval: 2016

Of course, we will continue to monitor this drug safety issue and report significant developments.

[View article at original source]

____________________________________________

Invokana / Glyxambi / Synjady

Free Case Evaluation

Strictly Confidential, No Obligation.

____________________________________________

Filed Under: Unsafe Drugs Tagged With: Bladder Cancer, diabetes drugs, diabetes drugs side effects, Glyxambi, Jardiance, Sodium-Glucose-Cotransporter-2 Inhibitors, Synjardy, Synjardy XR

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • PFAS Firefighter Gear Lawsuits
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.